• Miltefosine: Dual-Pathway Modulation for Leukopenia Research

  2026-06-16

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) redefines hematology and oncology research with its unique ability to concurrently inhibit the PI3K/Akt pathway and activate Ras/MEK/ERK signaling, restoring neutrophil counts and suppressing cancer cell proliferation. This article delivers actionable protocols and troubleshooting strategies, leveraging new evidence for advanced neutrophil differentiation and translational workflows.

• SCH772984: Precision ERK1/2 Inhibition for MAPK Pathway Rese

  2026-06-15

  SCH772984 stands out as a highly selective ERK1/2 inhibitor, enabling robust dissection of MAPK/ERK-driven signaling in models of BRAF, NRAS, and KRAS mutant cancers. This guide delivers actionable protocols and troubleshooting insights for maximizing reproducibility in both cell-based and in vivo experimental workflows.

• GLI2 Drives Tumor Immune Evasion via WNT and Prostaglandin S

  2026-06-15

  A recent study identifies GLI2 as a central regulator of tumor immune evasion and resistance to immunotherapy by orchestrating WNT and prostaglandin signaling. These mechanistic insights provide a foundation for developing combination strategies to overcome immunotherapeutic resistance in cancer.

• ETS1 Regulates SUMOylation-Mediated Mitophagy in BPD Models

  2026-06-14

  This study reveals that the transcription factor ETS1 ameliorates bronchopulmonary dysplasia (BPD) by modulating mitophagy through the SENP2/HSPA8/FUNDC1 axis. The findings highlight the therapeutic potential of targeting protein sumoylation dynamics to restore mitochondrial homeostasis in neonatal lung injury.

• Capecitabine in Tumor-Stroma Oncology: Mechanism to Model

  2026-06-13

  Explore how Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) is redefining translational oncology by integrating tumor-stroma complexity into preclinical models. This article bridges mechanistic insight and strategic workflow guidance, referencing patient-derived assembloid innovations and actionable experimental protocols—positioning APExBIO's Capecitabine as a cornerstone for next-generation drug discovery.

• gamma-Glu-Cys (γ-Glu-Cys): Protocols and QC for Research Use

  2026-06-12

  gamma-Glu-Cys (γ-Glu-Cys) is an essential substrate for the biosynthesis of L-glutathione and serves as a key intermediate in glutathione metabolism and thiol-reactive peptide synthesis. This product is best suited for controlled in vitro workflows requiring high-purity intermediates and strict solubility and storage parameters. It is not recommended for diagnostic or clinical applications.

• AT-406 (SM-406): Redefining Apoptosis Activation in Oncology

  2026-06-12

  This thought-leadership article explores AT-406 (SM-406)'s mechanistic and translational impact as a potent, orally bioavailable IAP antagonist for apoptosis pathway activation in cancer cells. Bridging recent insights in apoptosis modulation, competitive positioning, and the evolving landscape of translational oncology, it offers strategic guidance for researchers aiming to advance therapeutic innovation and precision in cancer research.

• Pam3CSK4 TFA: Precision Tool for Dissecting TLR1/2 Signaling

  2026-06-11

  Explore Pam3CSK4 TFA as a TLR1/2 agonist for advanced in vitro and in vivo studies. This article uniquely maps its utility to refined cytokine profiling and assay optimization in innate immunity research.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-06-11

  This study reveals distinct sex-dependent responses to angiotensin II-induced hypertension in conscious mice, showing that males develop a much greater increase in blood pressure than females. By integrating telemetry and hormonal manipulation, the research illuminates how sex hormones modulate cardiovascular regulation and baroreflex function, providing a critical model for future studies on adrenergic receptor signaling and cardiovascular disease.

• EZ Cap™ Cas9 mRNA (m1Ψ): Optimizing mRNA Design for Precisio

  2026-06-10

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ) leverages advanced mRNA engineering—including Cap1 structure and m1Ψ modification—for enhanced genome editing specificity, stability, and reduced immune response. This article uniquely analyzes translational and delivery parameters to maximize CRISPR-Cas9 assay outcomes.

• SM-164: Bivalent Smac Mimetic Empowering Cancer Research Ass

  2026-06-10

  SM-164, a potent bivalent Smac mimetic from APExBIO, delivers rapid, reproducible apoptosis induction in diverse tumor models by targeting IAPs with sub-nanomolar affinity. Explore how optimized workflows and troubleshooting strategies with SM-164 drive reliable caspase activation and TNFα-dependent apoptosis, advancing cancer research beyond conventional approaches.

• Dextrose (D-glucose) Workflows for Tumor Immunometabolism

  2026-06-09

  Dextrose (D-glucose) is a cornerstone for dissecting glucose metabolism in hypoxic tumor microenvironments and immunometabolic research. This guide delivers actionable workflows, protocol enhancements, and troubleshooting strategies for maximizing data reliability in advanced cellular assays.

• NMDA Receptor-Driven Cav2.1 Channel Recruitment in PV Intern

  2026-06-09

  This study demonstrates that NMDA receptor signaling is crucial for the maturation of GABAergic synaptic transmission from neocortical parvalbumin (PV) interneurons, specifically through the recruitment of Cav2.1 channels. The findings clarify how developmental NMDAR hypofunction can disrupt inhibitory control, offering mechanistic insight relevant to neurodevelopmental disorders like schizophrenia.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-06-08

  Xue et al. provide mechanistic insight into how male and female mice respond differently to chronic angiotensin II-induced hypertension, using conscious telemetry and surgical hormone manipulation. Their findings highlight the protective role of female sex hormones and altered baroreflex regulation in males, advancing the field’s understanding of sex as a critical biological variable in cardiovascular research.

• MDL 28170 Calpain Inhibitor: Protocols for Neuroprotection

  2026-06-08

  MDL 28170 enables precise, translational workflows for neuroprotection and apoptosis assays by offering high selectivity for calpain and cathepsin B, rapid CNS accessibility, and proven efficacy in advanced in vivo and cell-based models. Its role in safeguarding neuronal structure and cognition—especially following ischemic or surgical insults—makes it a cornerstone for mechanistic and therapeutic studies across neuroscience and beyond.

444 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page